EIF2AK3 and breast cancer: In this study, we set out to investigate whether ISRIB, by repressing p‐eIF2 alpha, which is upstream to ERO1 in the PERK branch of the ER stress response, also inhibits ERO1 activity, hence inhibiting tumour angiogenesis in breast cancer.